Search

Displaying results 4521 - 4530 of 5925 in total
  1. Drug

    Risvodetinib

    go.drugbank.com/drugs/DB21602
    Investigational

    Risvodetinib has a monoisotopic molecular weight of 574.28 Da.

  2. Drug

    SYNB1891

    go.drugbank.com/drugs/DB17541
    Investigational

    SYNB1891 is a live, modified strain of the probiotic _Escherichia coli_ Nissle engineered to produce cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway.

  3. Drug

    Nifurizone

    go.drugbank.com/drugs/DB19694
    Experimental

    Nifurizone has a monoisotopic molecular weight of 307.09 Da.

  4. Drug

    Onametostat

    go.drugbank.com/drugs/DB21480
    Investigational

    Onametostat has a monoisotopic molecular weight of 482.11 Da.

  5. Drug

    Mequitazine

    go.drugbank.com/drugs/DB01071
    Investigational

    It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  6. Drug

    Nifurethazone

    go.drugbank.com/drugs/DB20112
    Experimental

    Nifurethazone has a monoisotopic molecular weight of 269.11 Da.

  7. Drug

    Gamcemetinib

    go.drugbank.com/drugs/DB21624
    Investigational

    Gamcemetinib has a monoisotopic molecular weight of 469.1 Da.

  8. Drug

    Brincidofovir

    go.drugbank.com/drugs/DB12151
    ApprovedInvestigational

    [A235725,A235735] Due to its formulation as a pro-drug brincidofovir also carries a greater bioavailability than cidofovir,[A235740,A235725] allowing for oral administration rather than intravenous.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors
  9. Drug

    Pirtobrutinib

    go.drugbank.com/drugs/DB17472
    ApprovedInvestigational

    Its high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of atrial fibrillation.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  10. Drug

    Reproxalap

    go.drugbank.com/drugs/DB16688
    Investigational

    [L32990] NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.[L32990]